Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-09-04

AUTHORS

Hussien Ahmed, Abdelrahman Ibrahim Abushouk, Amr Menshawy, Arwa Mohamed, Ahmed Negida, Samah A. Loutfy, Mohamed M. Abdel-Daim

ABSTRACT

Background and objectiveInterferon-free regimens are rapidly evolving for patients with chronic hepatitis C virus (HCV) infection. We performed this meta-analysis to investigate the safety and efficacy of a combination regimen (ombitasvir [OBV]/paritaprevir [PTV]/ritonavir [r] ± dasabuvir [DSV]) for the treatment of patients with HCV genotype 1 infection.MethodsA computerized literature search for relevant clinical trials was conducted during May 2017. Data on sustained virological response (SVR), virological relapse, and safety outcomes were extracted and calculated as pooled proportion (PP) or risk ratio (RR) with their 95% confidence interval (CI), using StatsDirect and RevMan software.ResultsThe final analysis included 13 studies for HCV genotype 1 (3115 patients). The pooled effect estimate showed that 12-week treatment of genotype 1 patients with the OBV/PTV/r regimen achieved a high SVR rate (PP = 94%, 95% CI 92–96) that increased to (PP = 97%, 95% CI 96–98) upon the addition of DSV. These results were consistent when independent subgroup analyses were conducted based on viral subgenotypes, the presence of cirrhosis, or former treatment failure. Adding ribavirin (RBV) to this regimen was not associated with increased SVR rates (risk ratio = 1, 95% CI 0.98–1.02), while it increased the risk of serious adverse events (p = 0.02), insomnia (p = 0.001), and pruritus (p < 0.001).ConclusionThe current meta-analysis showed a high efficacy for the OBV/PTV/r regimen in the treatment of HCV genotype 1 (with DSV) infection, regardless of the presence of cirrhosis or former treatment failure. Adding RBV to this regimen slightly decreased the relapse rate. Future studies with larger sample sizes are required to investigate the efficacy of this regimen in other HCV genotypes and to establish the evidence about the effect of adding RBV to OBV/PTV/r + DSV. More... »

PAGES

1009-1023

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40261-017-0565-5

DOI

http://dx.doi.org/10.1007/s40261-017-0565-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1091478013

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28871475


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "2-Naphthylamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anilides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antiviral Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carbamates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclopropanes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genotype", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepacivirus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatitis C, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lactams, Macrocyclic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Macrocyclic Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proline", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribavirin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ritonavir", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonamides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sustained Virologic Response", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Student Research Unit, Zagazig University, Zagazig, El-Sharkia, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.31451.32", 
          "name": [
            "Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Egypt", 
            "Medical Research Group of Egypt, Cairo, Egypt", 
            "Student Research Unit, Zagazig University, Zagazig, El-Sharkia, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ahmed", 
        "givenName": "Hussien", 
        "id": "sg:person.07563437045.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07563437045.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Ain Shams University, Cairo, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.7269.a", 
          "name": [
            "Medical Research Group of Egypt, Cairo, Egypt", 
            "Faculty of Medicine, Ain Shams University, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abushouk", 
        "givenName": "Abdelrahman Ibrahim", 
        "id": "sg:person.01071425357.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071425357.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Faculty of Medicine, Al-Azhar University, Cairo, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.411303.4", 
          "name": [
            "Medical Research Group of Egypt, Cairo, Egypt", 
            "Faculty of Medicine, Al-Azhar University, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Menshawy", 
        "givenName": "Amr", 
        "id": "sg:person.012563374743.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012563374743.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Research Group of Egypt, Cairo, Egypt", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Egypt", 
            "Medical Research Group of Egypt, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mohamed", 
        "givenName": "Arwa", 
        "id": "sg:person.014747024627.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014747024627.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Student Research Unit, Zagazig University, Zagazig, El-Sharkia, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.31451.32", 
          "name": [
            "Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Egypt", 
            "Medical Research Group of Egypt, Cairo, Egypt", 
            "Student Research Unit, Zagazig University, Zagazig, El-Sharkia, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Negida", 
        "givenName": "Ahmed", 
        "id": "sg:person.01122536161.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122536161.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Institute, Cairo University, Cairo, Egypt", 
          "id": "http://www.grid.ac/institutes/grid.7776.1", 
          "name": [
            "National Cancer Institute, Cairo University, Cairo, Egypt"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Loutfy", 
        "givenName": "Samah A.", 
        "id": "sg:person.01365730704.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365730704.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, 41522, Ismailia, Egypt", 
            "Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abdel-Daim", 
        "givenName": "Mohamed M.", 
        "id": "sg:person.01030160012.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030160012.58"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/ajg.2015.203", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002224471", 
          "https://doi.org/10.1038/ajg.2015.203"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-09-04", 
    "datePublishedReg": "2017-09-04", 
    "description": "Background and objectiveInterferon-free regimens are rapidly evolving for patients with chronic hepatitis C virus (HCV) infection. We performed this meta-analysis to investigate the safety and efficacy of a combination regimen (ombitasvir [OBV]/paritaprevir [PTV]/ritonavir [r]\u00a0\u00b1\u00a0dasabuvir [DSV]) for the treatment of patients with HCV genotype 1\u00a0infection.MethodsA computerized literature search for relevant clinical trials was conducted during May 2017. Data on sustained virological response (SVR), virological relapse, and safety outcomes were extracted and calculated as pooled proportion (PP) or risk ratio (RR) with their 95% confidence interval (CI), using StatsDirect and RevMan software.ResultsThe final analysis included 13 studies for HCV genotype 1 (3115 patients). The pooled effect estimate showed that 12-week treatment of genotype 1 patients with the OBV/PTV/r regimen achieved a high SVR rate (PP\u00a0=\u00a094%, 95% CI 92\u201396) that increased to (PP\u00a0=\u00a097%, 95% CI 96\u201398) upon the addition of DSV. These results were consistent when independent subgroup analyses were conducted based on viral subgenotypes, the presence of cirrhosis, or former treatment failure. Adding ribavirin\u00a0(RBV) to this regimen was not associated with increased SVR rates (risk ratio\u00a0=\u00a01, 95% CI 0.98\u20131.02), while it increased the risk of serious adverse events (p\u00a0=\u00a00.02), insomnia (p\u00a0=\u00a00.001), and pruritus (p\u00a0<\u00a00.001).ConclusionThe current meta-analysis showed a high efficacy for the OBV/PTV/r regimen in the treatment of HCV genotype 1 (with DSV) infection, regardless of the presence of cirrhosis or former treatment failure. Adding RBV to this regimen slightly decreased the relapse rate. Future studies with larger sample sizes are required to investigate the efficacy of this regimen in other HCV genotypes and to establish the evidence about the effect of adding RBV to OBV/PTV/r\u00a0+\u00a0DSV.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40261-017-0565-5", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "sustained virological response", 
      "presence of cirrhosis", 
      "HCV genotype 1", 
      "genotype 1", 
      "r regimen", 
      "SVR rates", 
      "treatment failure", 
      "risk ratio", 
      "chronic hepatitis C virus (HCV) infection", 
      "OBV/PTV/r", 
      "ombitasvir/paritaprevir/ritonavir", 
      "hepatitis C virus genotype 1", 
      "hepatitis C virus infection", 
      "HCV genotype 1 infection", 
      "C virus genotype 1", 
      "paritaprevir/ritonavir", 
      "C virus infection", 
      "genotype 1 patients", 
      "high SVR rates", 
      "serious adverse events", 
      "genotype 1 infection", 
      "pooled effect estimates", 
      "treatment of patients", 
      "relevant clinical trials", 
      "confidence intervals", 
      "computerized literature search", 
      "free regimens", 
      "virological response", 
      "virological relapse", 
      "combination regimen", 
      "adverse events", 
      "relapse rate", 
      "HCV genotypes", 
      "RevMan software", 
      "subgroup analysis", 
      "clinical trials", 
      "virus infection", 
      "safety outcomes", 
      "regimen", 
      "ribavirin", 
      "larger sample size", 
      "systematic review", 
      "Meta-Analysis", 
      "literature search", 
      "patients", 
      "final analysis", 
      "effect estimates", 
      "infection", 
      "high efficacy", 
      "efficacy", 
      "cirrhosis", 
      "treatment", 
      "viral subgenotypes", 
      "future studies", 
      "sample size", 
      "safety", 
      "dasabuvir", 
      "pruritus", 
      "regimens", 
      "relapse", 
      "failure", 
      "ritonavir", 
      "StatsDirect", 
      "insomnia", 
      "proportion", 
      "trials", 
      "subgenotypes", 
      "DSV", 
      "outcomes", 
      "rate", 
      "risk", 
      "study", 
      "review", 
      "presence", 
      "genotypes", 
      "response", 
      "interval", 
      "evidence", 
      "background", 
      "events", 
      "effect", 
      "analysis", 
      "search", 
      "data", 
      "addition", 
      "ratio", 
      "results", 
      "size", 
      "estimates", 
      "software"
    ], 
    "name": "Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis", 
    "pagination": "1009-1023", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1091478013"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40261-017-0565-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28871475"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40261-017-0565-5", 
      "https://app.dimensions.ai/details/publication/pub.1091478013"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_726.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40261-017-0565-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0565-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0565-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0565-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-017-0565-5'


 

This table displays all metadata directly associated to this object as RDF triples.

302 TRIPLES      21 PREDICATES      137 URIs      127 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40261-017-0565-5 schema:about N0f1b143383524d0faa798a8fd544feaa
2 N0fcb763da2914ac993e0f35c4fd11e1f
3 N200e598e2a4c4638b4e9564335f4c3cb
4 N22a979f2c7564872970f3a174a246fb4
5 N3743f3788b6f466a9b84b80aa0e3d855
6 N4e2d31e9722b44d3bed0b14f245b5593
7 N5a76153f81c74e98bc7032e3f43049a3
8 N653c363ad4b449ae9e3176a877f0bd99
9 N6793d9d120f74af997d461f1c68591cb
10 N75671d44f6cf4f2986e11a495b343940
11 Na2f8f18be3384315871892ed34946d01
12 Na65a5380dc374bdd9af37b5e92304595
13 Nae075fdbcd354b0dbdcd78a447be2e71
14 Nb4cd006b786543a8bb900dd19630a85a
15 Nb994b380c08d4a99b39f8a716e3791de
16 Nc15d2b16706944169a08c498a028ff8e
17 Nd42ed4616f2e40b9bba85fec70a191fb
18 Nd595e8cd36cd4c67940a71024fffaec9
19 Nda30e1b476e347129e08b843dfa5b4df
20 Nfe636401321c4ce895be4c169de0b132
21 anzsrc-for:11
22 anzsrc-for:1103
23 anzsrc-for:1117
24 schema:author N6ad43ab4412e4dd4abf6733e626926c2
25 schema:citation sg:pub.10.1038/ajg.2015.203
26 schema:datePublished 2017-09-04
27 schema:datePublishedReg 2017-09-04
28 schema:description Background and objectiveInterferon-free regimens are rapidly evolving for patients with chronic hepatitis C virus (HCV) infection. We performed this meta-analysis to investigate the safety and efficacy of a combination regimen (ombitasvir [OBV]/paritaprevir [PTV]/ritonavir [r] ± dasabuvir [DSV]) for the treatment of patients with HCV genotype 1 infection.MethodsA computerized literature search for relevant clinical trials was conducted during May 2017. Data on sustained virological response (SVR), virological relapse, and safety outcomes were extracted and calculated as pooled proportion (PP) or risk ratio (RR) with their 95% confidence interval (CI), using StatsDirect and RevMan software.ResultsThe final analysis included 13 studies for HCV genotype 1 (3115 patients). The pooled effect estimate showed that 12-week treatment of genotype 1 patients with the OBV/PTV/r regimen achieved a high SVR rate (PP = 94%, 95% CI 92–96) that increased to (PP = 97%, 95% CI 96–98) upon the addition of DSV. These results were consistent when independent subgroup analyses were conducted based on viral subgenotypes, the presence of cirrhosis, or former treatment failure. Adding ribavirin (RBV) to this regimen was not associated with increased SVR rates (risk ratio = 1, 95% CI 0.98–1.02), while it increased the risk of serious adverse events (p = 0.02), insomnia (p = 0.001), and pruritus (p < 0.001).ConclusionThe current meta-analysis showed a high efficacy for the OBV/PTV/r regimen in the treatment of HCV genotype 1 (with DSV) infection, regardless of the presence of cirrhosis or former treatment failure. Adding RBV to this regimen slightly decreased the relapse rate. Future studies with larger sample sizes are required to investigate the efficacy of this regimen in other HCV genotypes and to establish the evidence about the effect of adding RBV to OBV/PTV/r + DSV.
29 schema:genre article
30 schema:isAccessibleForFree false
31 schema:isPartOf N387ce7f2513c4dd8845f81ba7335a2db
32 Nee5484dd1e1042ddb434265497b27d49
33 sg:journal.1100199
34 schema:keywords C virus genotype 1
35 C virus infection
36 DSV
37 HCV genotype 1
38 HCV genotype 1 infection
39 HCV genotypes
40 Meta-Analysis
41 OBV/PTV/r
42 RevMan software
43 SVR rates
44 StatsDirect
45 addition
46 adverse events
47 analysis
48 background
49 chronic hepatitis C virus (HCV) infection
50 cirrhosis
51 clinical trials
52 combination regimen
53 computerized literature search
54 confidence intervals
55 dasabuvir
56 data
57 effect
58 effect estimates
59 efficacy
60 estimates
61 events
62 evidence
63 failure
64 final analysis
65 free regimens
66 future studies
67 genotype 1
68 genotype 1 infection
69 genotype 1 patients
70 genotypes
71 hepatitis C virus genotype 1
72 hepatitis C virus infection
73 high SVR rates
74 high efficacy
75 infection
76 insomnia
77 interval
78 larger sample size
79 literature search
80 ombitasvir/paritaprevir/ritonavir
81 outcomes
82 paritaprevir/ritonavir
83 patients
84 pooled effect estimates
85 presence
86 presence of cirrhosis
87 proportion
88 pruritus
89 r regimen
90 rate
91 ratio
92 regimen
93 regimens
94 relapse
95 relapse rate
96 relevant clinical trials
97 response
98 results
99 review
100 ribavirin
101 risk
102 risk ratio
103 ritonavir
104 safety
105 safety outcomes
106 sample size
107 search
108 serious adverse events
109 size
110 software
111 study
112 subgenotypes
113 subgroup analysis
114 sustained virological response
115 systematic review
116 treatment
117 treatment failure
118 treatment of patients
119 trials
120 viral subgenotypes
121 virological relapse
122 virological response
123 virus infection
124 schema:name Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis
125 schema:pagination 1009-1023
126 schema:productId N2002e64c6e4e486f87c94c2b30a16fb9
127 N25b10766f87e4484a4e5661bbd02f27c
128 N840530b93cb4403c83746b1936bef012
129 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091478013
130 https://doi.org/10.1007/s40261-017-0565-5
131 schema:sdDatePublished 2022-12-01T06:36
132 schema:sdLicense https://scigraph.springernature.com/explorer/license/
133 schema:sdPublisher Ncf421dcf6c57490c9c20fd39bd1e2b2c
134 schema:url https://doi.org/10.1007/s40261-017-0565-5
135 sgo:license sg:explorer/license/
136 sgo:sdDataset articles
137 rdf:type schema:ScholarlyArticle
138 N0f1b143383524d0faa798a8fd544feaa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Antiviral Agents
140 rdf:type schema:DefinedTerm
141 N0fcb763da2914ac993e0f35c4fd11e1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Hepacivirus
143 rdf:type schema:DefinedTerm
144 N2002e64c6e4e486f87c94c2b30a16fb9 schema:name doi
145 schema:value 10.1007/s40261-017-0565-5
146 rdf:type schema:PropertyValue
147 N200e598e2a4c4638b4e9564335f4c3cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Sulfonamides
149 rdf:type schema:DefinedTerm
150 N22a979f2c7564872970f3a174a246fb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Sustained Virologic Response
152 rdf:type schema:DefinedTerm
153 N25b10766f87e4484a4e5661bbd02f27c schema:name dimensions_id
154 schema:value pub.1091478013
155 rdf:type schema:PropertyValue
156 N33c0511f2b4d40d4a5cae09de291b420 rdf:first sg:person.014747024627.32
157 rdf:rest N3b1bb50dd86f4332941eb4ff08cfe8e4
158 N3743f3788b6f466a9b84b80aa0e3d855 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Cyclopropanes
160 rdf:type schema:DefinedTerm
161 N387ce7f2513c4dd8845f81ba7335a2db schema:volumeNumber 37
162 rdf:type schema:PublicationVolume
163 N3b1bb50dd86f4332941eb4ff08cfe8e4 rdf:first sg:person.01122536161.09
164 rdf:rest N45d3d7143f074549bed07915269b23cb
165 N45d3d7143f074549bed07915269b23cb rdf:first sg:person.01365730704.61
166 rdf:rest Ne40bfbae6b364b8aa0016771d51a8a21
167 N4e2d31e9722b44d3bed0b14f245b5593 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name 2-Naphthylamine
169 rdf:type schema:DefinedTerm
170 N5a76153f81c74e98bc7032e3f43049a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Genotype
172 rdf:type schema:DefinedTerm
173 N653c363ad4b449ae9e3176a877f0bd99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Valine
175 rdf:type schema:DefinedTerm
176 N6793d9d120f74af997d461f1c68591cb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Liver Cirrhosis
178 rdf:type schema:DefinedTerm
179 N6ad43ab4412e4dd4abf6733e626926c2 rdf:first sg:person.07563437045.65
180 rdf:rest Neb7b045efaad4d378a0d29bf3a070633
181 N75671d44f6cf4f2986e11a495b343940 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Anilides
183 rdf:type schema:DefinedTerm
184 N840530b93cb4403c83746b1936bef012 schema:name pubmed_id
185 schema:value 28871475
186 rdf:type schema:PropertyValue
187 Na2f8f18be3384315871892ed34946d01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Ribavirin
189 rdf:type schema:DefinedTerm
190 Na65a5380dc374bdd9af37b5e92304595 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Macrocyclic Compounds
192 rdf:type schema:DefinedTerm
193 Nae075fdbcd354b0dbdcd78a447be2e71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Ritonavir
195 rdf:type schema:DefinedTerm
196 Nb4cd006b786543a8bb900dd19630a85a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Uracil
198 rdf:type schema:DefinedTerm
199 Nb994b380c08d4a99b39f8a716e3791de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Carbamates
201 rdf:type schema:DefinedTerm
202 Nc1526f58f433474a94ae593216184145 rdf:first sg:person.012563374743.05
203 rdf:rest N33c0511f2b4d40d4a5cae09de291b420
204 Nc15d2b16706944169a08c498a028ff8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Proline
206 rdf:type schema:DefinedTerm
207 Ncf421dcf6c57490c9c20fd39bd1e2b2c schema:name Springer Nature - SN SciGraph project
208 rdf:type schema:Organization
209 Nd42ed4616f2e40b9bba85fec70a191fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Humans
211 rdf:type schema:DefinedTerm
212 Nd595e8cd36cd4c67940a71024fffaec9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Lactams, Macrocyclic
214 rdf:type schema:DefinedTerm
215 Nda30e1b476e347129e08b843dfa5b4df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Drug Therapy, Combination
217 rdf:type schema:DefinedTerm
218 Ne40bfbae6b364b8aa0016771d51a8a21 rdf:first sg:person.01030160012.58
219 rdf:rest rdf:nil
220 Neb7b045efaad4d378a0d29bf3a070633 rdf:first sg:person.01071425357.16
221 rdf:rest Nc1526f58f433474a94ae593216184145
222 Nee5484dd1e1042ddb434265497b27d49 schema:issueNumber 11
223 rdf:type schema:PublicationIssue
224 Nfe636401321c4ce895be4c169de0b132 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Hepatitis C, Chronic
226 rdf:type schema:DefinedTerm
227 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
228 schema:name Medical and Health Sciences
229 rdf:type schema:DefinedTerm
230 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
231 schema:name Clinical Sciences
232 rdf:type schema:DefinedTerm
233 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
234 schema:name Public Health and Health Services
235 rdf:type schema:DefinedTerm
236 sg:journal.1100199 schema:issn 1173-2563
237 1179-1918
238 schema:name Clinical Drug Investigation
239 schema:publisher Springer Nature
240 rdf:type schema:Periodical
241 sg:person.01030160012.58 schema:affiliation grid-institutes:grid.268441.d
242 schema:familyName Abdel-Daim
243 schema:givenName Mohamed M.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030160012.58
245 rdf:type schema:Person
246 sg:person.01071425357.16 schema:affiliation grid-institutes:grid.7269.a
247 schema:familyName Abushouk
248 schema:givenName Abdelrahman Ibrahim
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071425357.16
250 rdf:type schema:Person
251 sg:person.01122536161.09 schema:affiliation grid-institutes:grid.31451.32
252 schema:familyName Negida
253 schema:givenName Ahmed
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122536161.09
255 rdf:type schema:Person
256 sg:person.012563374743.05 schema:affiliation grid-institutes:grid.411303.4
257 schema:familyName Menshawy
258 schema:givenName Amr
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012563374743.05
260 rdf:type schema:Person
261 sg:person.01365730704.61 schema:affiliation grid-institutes:grid.7776.1
262 schema:familyName Loutfy
263 schema:givenName Samah A.
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365730704.61
265 rdf:type schema:Person
266 sg:person.014747024627.32 schema:affiliation grid-institutes:None
267 schema:familyName Mohamed
268 schema:givenName Arwa
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014747024627.32
270 rdf:type schema:Person
271 sg:person.07563437045.65 schema:affiliation grid-institutes:grid.31451.32
272 schema:familyName Ahmed
273 schema:givenName Hussien
274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07563437045.65
275 rdf:type schema:Person
276 sg:pub.10.1038/ajg.2015.203 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002224471
277 https://doi.org/10.1038/ajg.2015.203
278 rdf:type schema:CreativeWork
279 grid-institutes:None schema:alternateName Medical Research Group of Egypt, Cairo, Egypt
280 schema:name Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Egypt
281 Medical Research Group of Egypt, Cairo, Egypt
282 rdf:type schema:Organization
283 grid-institutes:grid.268441.d schema:alternateName Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan
284 schema:name Department of Ophthalmology and Micro-Technology, Yokohama City University, Yokohama, Japan
285 Pharmacology Department, Faculty of Veterinary Medicine, Suez Canal University, 41522, Ismailia, Egypt
286 rdf:type schema:Organization
287 grid-institutes:grid.31451.32 schema:alternateName Student Research Unit, Zagazig University, Zagazig, El-Sharkia, Egypt
288 schema:name Faculty of Medicine, Zagazig University, Zagazig, El-Sharkia, Egypt
289 Medical Research Group of Egypt, Cairo, Egypt
290 Student Research Unit, Zagazig University, Zagazig, El-Sharkia, Egypt
291 rdf:type schema:Organization
292 grid-institutes:grid.411303.4 schema:alternateName Faculty of Medicine, Al-Azhar University, Cairo, Egypt
293 schema:name Faculty of Medicine, Al-Azhar University, Cairo, Egypt
294 Medical Research Group of Egypt, Cairo, Egypt
295 rdf:type schema:Organization
296 grid-institutes:grid.7269.a schema:alternateName Faculty of Medicine, Ain Shams University, Cairo, Egypt
297 schema:name Faculty of Medicine, Ain Shams University, Cairo, Egypt
298 Medical Research Group of Egypt, Cairo, Egypt
299 rdf:type schema:Organization
300 grid-institutes:grid.7776.1 schema:alternateName National Cancer Institute, Cairo University, Cairo, Egypt
301 schema:name National Cancer Institute, Cairo University, Cairo, Egypt
302 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...